OrthoPediatrics

KIDS

Market cap $446M

WARSAW, Ind., Oct. 15, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2025 financial results on October 28, 2025 after the market closes. OrthoPediatrics will host a conference call on Tuesday, October 28, 2025 at 4:30 p.m. ET to discuss the results.

OrthoPediatrics Corp. (NASDAQ:KIDS ) Q3 2025 Sales Call October 9, 2025 4:30 PM EDT Company Participants David Bailey - President, CEO & Director Fred Hite - CFO, Principal Financial & Accounting Officer, COO and Director Conference Call Participants Hannah Jeffrey - The Gilmartin Group Ryan Zimmerman - BTIG, LLC, Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Ravi Misra - Truist Securities, Inc., Research Division Joseph Conway - Needham & Company, LLC, Research Division David Turkaly - Citizens JMP Securities, LLC, Research Division Presentation Operator Good afternoon, and welcome to the OrthoPediatrics Corporation's Third Quarter 2025 Preliminary Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

Company to host conference call today, October 9th, 2025, to discuss the financial results and updated outlook Company to host conference call today, October 9th, 2025, to discuss the financial results and updated outlook

WARSAW, Ind., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the completion of the first U.S. surgical procedures with the VerteGlide Spinal Growth Guidance System (“VerteGlide”), used to treat Early Onset Scoliosis (“EOS”).

WARSAW, Ind., Sept. 05, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics announced today a new distribution partnership with MY01, an innovative medical technology company focused on transforming the diagnosis of limb perfusion injuries.

WARSAW, Ind., Aug. 25, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the appointment of Kelly Fischer to its Board of Directors effective as of August 8, 2025. The appointment was made concurrent with the announcement of the retirement of Terry Schlotterback from the OrthoPediatrics Board of Directors, effective as of August 8, 2025.

OrthoPediatrics Corp. (NASDAQ:KIDS ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants David R. Bailey - President, CEO & Director Fred L.

OrthoPediatrics (KIDS) Q2 Revenue Up 16%

While the top- and bottom-line numbers for OrthoPediatrics (KIDS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

OrthoPediatrics (KIDS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.23 per share a year ago.